Bio-Techne Corporation (TECH)
Should You Continue to Retain Bio-Techne Stock in Your Portfolio?
Bio-Techne's success with four growth verticals and expansion through acquisitions bode well.
Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
Bio-Techne Corporation (TECH) Q1 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH ) Q1 2025 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President and Chief Executive Officer Jim Hippel - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Jacob Johnson - Stephens Dan Leonard - UBS Thomas DeBourcy - Nephron Research Justin Bowers - Deutsche Bank Tom Peterson - Baird Matt Larew - William Blair Sung Ji Nam - Scotiabank Operator Good morning, and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2025. At this time, all participants have been placed in listen-only mode and the call will be open for questions following management's prepared remarks.
Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket
TECH registers continued momentum across its Diagnostics & Spatial Biology segment.
Techne (TECH) Beats Q1 Earnings and Revenue Estimates
Techne (TECH) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.41 per share a year ago.
Bio-Techne beats quarterly profit estimates, driven by diagnostic unit growth; shares rise
Bio-Techne beat first-quarter profit estimates on Wednesday helped by growth in its diagnostics and spatial biology segment, sending the shares of the biotech company up 4.59% in premarket trading.
Techne (TECH) Misses Q4 Earnings and Revenue Estimates
Techne (TECH) came out with quarterly earnings of $0.49 per share, missing the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.55 per share a year ago.
Bio-Techne meets Q4 profit estimates on demand for its diagnostics products
Bio-Techne reported fourth-quarter profit in line with estimates on Wednesday as growth in the diagnostics and genomics unit offset weakness in its protein sciences unit.
GMAB or TECH: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
GMAB vs. TECH: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
